Chapter 16. Membranoproliferative Glomerulonephritis

  1. Donald A. Molony MD2,3 and
  2. Jonathan C. Craig MD, PhD4,5
  1. Richard J. Glassock MD

Published Online: 4 MAR 2009

DOI: 10.1002/9781444303391.ch16

Evidence-Based Nephrology

Evidence-Based Nephrology

How to Cite

Glassock, R. J. (2008) Membranoproliferative Glomerulonephritis, in Evidence-Based Nephrology (eds D. A. Molony and J. C. Craig), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303391.ch16

Editor Information

  1. 2

    Division of Renal Disease and Hypertension, University of Texas, USA

  2. 3

    Houston Medical School, Houston, Texas, USA

  3. 4

    School of Public Health, University of Sydney, Australia

  4. 5

    Department of Nephrology, The Children's Hospital at Westmead, Sydney, Australia

Author Information

  1. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA

Publication History

  1. Published Online: 4 MAR 2009
  2. Published Print: 5 DEC 2008

ISBN Information

Print ISBN: 9781405139755

Online ISBN: 9781444303391



  • membrano proliferative glomerulonephritis (MPGN);
  • suggested algorithm for evaluation and treatment of MPGN;
  • evidence base for treatment decisions;
  • nonsteroidal anti-inflammatory drugs (NSAIDs);
  • nephritis associated with systemic lupus erythematosus (SLE);
  • membrano proliferative pattern by light microscopy


This chapter contains sections titled:

  • Introduction

  • Classification

  • Clinical features and natural history

  • Evidence base for treatment decisions

  • Summary and recommendations

  • References